PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts describing research with Advaxis Lm-LLO immunotherapies have been selected for oral and poster presentations at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting, October 26-28, 2012 at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, MD.
Abstract 1452783 titled “ADXS11-001 Lm-LLO immunotherapy targeting HPV-E7: preliminary safety and survival data from a Phase 2 study in Indian women with recurrent/refractory cervical cancer” has been selected for oral presentation during the Combining Immunotherapy and Other Therapies session to be held on October 27, 2012 from 8:45 AM to 11:30 AM. Dr. Robert Petit, VP of Clinical Operations and Medical Affairs at Advaxis, will present updated safety and efficacy data from the ongoing trial.
Abstract 1452633 titled “Development of bivalent Listeria monocytogenes-LLO immunotherapy that concomitantly targets tumor cells and angiogenesis” has been selected for poster presentation at the Targeted Therapies and Anti-Tumor Immunity session to be held during the Annual Meeting. Dr. Anu Wallecha, Director of Research and Development at Advaxis, will report on the preclinical development of a bivalent Lm-LLO immunotherapy using a novel strain of attenuated Listeria that delivers two antigen-adjuvant fusion proteins from a single bacterial vector. This construct targets two different antigens, one tumor-associated antigen and a non-specific antigen targeting the tumor’s blood supply.
“With the clinical data to be presented at SITC, Advaxis continues to demonstrate the utility of our novel technology for the treatment of cancer,” commented Dr. John Rothman, EVP of Science and Operations at Advaxis. “The commitment of Advaxis to develop new and potentially more versatile strains of Listeria to treat disease is exemplified by the work we will present on a bivalent Lm-LLO vector.”
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
In April 2012, Advaxis’ lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the World Vaccine Congress website.
ADXS-HPV is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neck cancer (University of Liverpool/CRUK UK study, Clinical Trials.gov Identifier NCT0CT01598792). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn
Forward-Looking Statements
This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2011, which is available at www.sec.gov. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.